The pharmacology of verapamil. III. Pharmacokinetics in normal subjects after intravenous drug administration
- PMID: 6160352
- DOI: 10.1097/00005344-198101000-00003
The pharmacology of verapamil. III. Pharmacokinetics in normal subjects after intravenous drug administration
Abstract
The pharmacokinetics of verapamil were determined in 8 normal male subjects (age range, 24-28 years) after administration of 0.2 mg/kg over a 3-4 min period. Plasma drug concentrations were measured by a gas-chromatographic method using a nitrogen-specific detector with a sensitivity of 5 ng/ml. Verapamil levels fell in a biexponential pattern, and the data were fitted to a two-compartment model with the NONLIN computer program. The distribution phase half-life was 3.51 min and that of the elimination phase, 110.5 min; the volume of distribution was 178 +/- 26 liters, and the plasma clearance ws 1.06 +/- 0.27 liters/min. The P-R interval of the surface electrocardiogram was increased in each subject in direct proportion to the verapamil plasma level, but with considerable between-subject variability. One subject developed transient Mobitz I block at a plasma drug concentration of 162 ng/ml. At peak verapamil concentrations, mean T-wave amplitude decreased 35 +/- 11% from control height. The results of this study suggest that P-R interval prolongation can be used as an indication of verapamil effect in patients with sinus rhythm.
Similar articles
-
Clinical pharmacokinetics of verapamil.Clin Pharmacokinet. 1984 Jan-Feb;9(1):26-41. doi: 10.2165/00003088-198409010-00002. Clin Pharmacokinet. 1984. PMID: 6362951 Review.
-
The pharmacology of verapamil. I. Elimination kinetics in dogs and correlation of plasma levels with effect on the eletrocardiogram.J Pharmacol Exp Ther. 1977 Jul;202(1):38-44. J Pharmacol Exp Ther. 1977. PMID: 874818
-
Pharmacokinetics of verapamil in man.Res Commun Chem Pathol Pharmacol. 1979 Apr;24(1):37-47. Res Commun Chem Pathol Pharmacol. 1979. PMID: 432439
-
The pharmacology of verapamil. IV. Kinetic and dynamic effects after single intravenous and oral doses.Clin Pharmacol Ther. 1982 Apr;31(4):418-26. doi: 10.1038/clpt.1982.54. Clin Pharmacol Ther. 1982. PMID: 7060323 Clinical Trial.
-
Kinetics and dynamics of calcium entry antagonists in systemic hypertension.Am J Cardiol. 1986 Feb 26;57(7):16D-21D. doi: 10.1016/0002-9149(86)90800-3. Am J Cardiol. 1986. PMID: 3513512 Review.
Cited by
-
Calcium antagonists. Pharmacokinetic properties.Drugs. 1983 Feb;25(2):113-24. doi: 10.2165/00003495-198325020-00002. Drugs. 1983. PMID: 6339196 Review.
-
Clinical pharmacokinetics of verapamil.Clin Pharmacokinet. 1984 Jan-Feb;9(1):26-41. doi: 10.2165/00003088-198409010-00002. Clin Pharmacokinet. 1984. PMID: 6362951 Review.
-
Pharmacokinetics of verapamil in patients with renal failure.Eur J Clin Pharmacol. 1985;28(4):405-10. doi: 10.1007/BF00544358. Eur J Clin Pharmacol. 1985. PMID: 4029246
-
Endovascular treatment of medically refractory cerebral vasospasm following aneurysmal subarachnoid hemorrhage.AJNR Am J Neuroradiol. 2010 Nov;31(10):1911-6. doi: 10.3174/ajnr.A2183. Epub 2010 Jul 8. AJNR Am J Neuroradiol. 2010. PMID: 20616179 Free PMC article.
-
Verapamil disposition and cardiovascular effects in elderly patients after single intravenous and oral doses.Cardiovasc Drugs Ther. 1989 Jun;3(3):417-25. doi: 10.1007/BF01858113. Cardiovasc Drugs Ther. 1989. PMID: 2487538
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials